Navidea Biopharmaceuticals (NAVB)
NYSE MKT:NAVB

Navidea (NAVB) Stock Price & Analysis

277 Followers

NAVB Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$0.08 - $1.05
Previous Close$0.09
Volume3.13M
Average Volume (3M)1.90M
Market Cap
$3.16M
Enterprise Value$3.78M
Total Cash (Recent Filing)$33.80K
Total Debt (Recent Filing)$354.37K
Price to Earnings (P/E)-0.2
Beta-0.23
Aug 09, 2023
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.50
Shares Outstanding35,064,475
10 Day Avg. Volume9,516,051
30 Day Avg. Volume1,897,907
Standard Deviation0.35
R-Squared0.05
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue257.83
Enterprise Value/Gross Profit-28.19
Enterprise Value/Ebitda-0.43
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0


Financials

Annual

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

Product Insights

Sorry, No Data Available
There is no website visitor data available for this stock.

---

NAVB FAQ

What was Navidea Biopharmaceuticals’s price range in the past 12 months?
Navidea Biopharmaceuticals lowest stock price was $0.08 and its highest was $1.05 in the past 12 months.
    What is Navidea Biopharmaceuticals’s market cap?
    Currently, no data Available
    When is Navidea Biopharmaceuticals’s upcoming earnings report date?
    Navidea Biopharmaceuticals’s upcoming earnings report date is Aug 09, 2023 which is in 69 days.
      How were Navidea Biopharmaceuticals’s earnings last quarter?
      Navidea Biopharmaceuticals released its earnings results on May 09, 2023. The company reported -$0.045 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.045.
        Is Navidea Biopharmaceuticals overvalued?
        According to Wall Street analysts Navidea Biopharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
          Does Navidea Biopharmaceuticals pay dividends?
          Navidea Biopharmaceuticals does not currently pay dividends.
          What is Navidea Biopharmaceuticals’s EPS estimate?
          Navidea Biopharmaceuticals’s EPS estimate for its next earnings report is not yet available.
          How many shares outstanding does Navidea Biopharmaceuticals have?
          Navidea Biopharmaceuticals has 35,064,476 shares outstanding.
            What happened to Navidea Biopharmaceuticals’s price movement after its last earnings report?
            Navidea Biopharmaceuticals reported an EPS of -$0.045 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -11.111%.
              Which hedge fund is a major shareholder of Navidea Biopharmaceuticals?
              Currently, no hedge funds are holding shares in NAVB

              ---

              Navidea Stock Smart Score

              N/A
              Not Ranked
              1
              2
              3
              4
              5
              6
              7
              8
              9
              10

              Technicals

              SMA
              Negative
              20 days / 200 days
              Momentum
              -88.91%
              12-Months-Change

              Fundamentals

              Return on Equity
              Trailing 12-Months
              Asset Growth
              -34.27%
              Trailing 12-Months
              This stock does not have enough of the key information we need to rate it accurately. Smart Score is calculated for stocks traded in Nasdaq, NYSE, TSE and LSE with a market cap above $30M and average 3 months trading volume above $30K.
              Learn more about TipRanks Smart Score

              Company Description

              Navidea Biopharmaceuticals

              Navidea Biopharmaceuticals, Inc. engages in the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates through the following segments: Diagnostics, Therapeutics, and Corporate. The company was founded in 1983 and is headquartered in Dublin, OH.

              ---

              Top 5 ETFs holding NAVB

              Name
              Market Value
              Smart Score
              iShares Core S&P Total U.S. Stock Market ETF
              $703.08
              8
              Up to five ETFs with an Outperform Smart Score that hold NAVB. The ETFs are listed according to market value of NAVB within the ETF

              ---

              Forecast EPS vs Actual EPS


              Similar Stocks
              Company
              Price & Change
              Follow
              NovelStem International
              Soleno Therapeutics
              Ensysce Biosciences
              Statera BioPharma

              Popular Stocks

              ---
              What's Included in PREMIUM?
              Make informed decisions based on Top Analysts' activity
              Know what industry insiders are buying
              Get actionable alerts from top Wall Street Analysts
              Find out before anyone else which stock is going to shoot up
              Get powerful stock screeners & detailed portfolio analysis